Skip to main content
. 2014 Feb 4;9(2):e86789. doi: 10.1371/journal.pone.0086789

Figure 3. Overall survival (OS) in KRAS mutant mCRC patients who had used and never-used oxaliplatin-based regimens.

Figure 3